OraSure Technologies, Inc. (OSUR)
NASDAQ • Healthcare
Last close at October 23, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, OraSure Technologies, Inc. keeps $20 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 4
in 11 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
OraSure Technologies’ revenue topped consensus in the second fiscal quarter of 2026, reported August 5, 2026, even as sales slipped year over year. Revenue fell 1.9% to about $30.6 million (down from roughly $31.2 million a year ago) but came in above expectations, with revenue of $30.6 million topping the $29.1 million estimate, +5%. The business spans Diagnostics and Molecular Solutions, and gross profit of about $13.3 million translated to a gross margin near 44%. Cash generation was negative in the quarter, with negative operating cash flow of about $9.9 million, while the company repurchased roughly $2.0 million of stock. For the next period, consensus calls for EPS of -$0.23 on revenue of $31.1 million.
Next report — what to expect
OraSure Technologies, Inc. (OSUR) reports on November 4, 2026. Wall Street expects EPS of -$0.18 on revenue of $31.1 million. For trailing context, revenue declined -1.9% year over year last quarter. The company has beaten EPS in 1 of its 8 most recent quarters, making variance versus consensus a key watch point.
About OraSure Technologies, Inc.
OraSure Technologies, Inc. develops, produces, and commercializes oral fluid diagnostic solutions and specimen collection tools. Listed on NASDAQ as OSUR, the company operates in healthcare through medical testing supplies and sample-collection products. It generated $115.0 million of revenue in FY2025.
Today's Snapshot
The day ended with OSUR 8.7% higher at 4.13, outperforming a weaker sector. Shares changed hands at roughly twice its usual level. Craig-Hallum analyst initiated coverage with a Buy rating and a $7 price target.
Trading Volume
Above 10d avg 545.3K
1.1M
vs S&P 500 Today
Strong Outperformance
+9.20%
Updated: October 23, 2026 at 20:22 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$3.39 - $3.85Buy
- RSI (14)61.32Neutral
- Stochastic %K (14, 3, 3)60.40Neutral
- MACD Level (12, 26)0.03Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.